Shares of Uniqure NV (NASDAQ:QURE) are trading down considerably following the company’s Third Quarter financial reults reported this morning. The company reported a net loss on the quarter of $27.3 million, and continues to bleed capital.
With that said, the first cohort of five hemophilia B patients have now been dosed in their Phase 1/2 study of AMT-060. The company hopes to remain on schedule to release preliminary data on two patients who have undergone 12 weeks of the treatment. These reults will be reported on in January of next year.
On a separate note, Uniqure NV (NASDAQ:QURE) is aggressively moving forward to complete their in-license of data from their collaborator.The stock is down 15.87% or $3.57 after the negative news, hitting $18.93 per share. About 472,175 shares traded hands or 66.88% up from the average. QURE has declined 12.55% since April 27, 2015 and is downtrending. It has underperformed by 11.66% the S&P500.
Out of 6 analysts covering uniQure N.V. (NASDAQ:QURE), 6 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $50 is the highest target while $33 is the lowest. The $42.20 average target is 122.93% above today’s ($18.93) stock price. uniQure N.V. was the topic in 11 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Chardan Capital Markets maintained the stock on October 1 with “Buy” rating. Piper Jaffray maintained it with “Overweight” rating and $40 target price in an August 28 report. Piper Jaffray maintained the shares of QURE in a report on September 21 with “Buy” rating. Finally, Oppenheimer maintained the stock with “Outperform” rating in a September 21 report.
Uniqure NV is a pharmaceutical company based in the Netherlands. The company has a market cap of $404.95 million. It is primarily engaged in the field of gene therapy for orphan diseases. It currently has negative earnings. The Firm is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.